Stay updated on Reversing Therapy Resistance: Epigenetic-Immune Clinical Trial
Sign up to get notified when there's something new on the Reversing Therapy Resistance: Epigenetic-Immune Clinical Trial page.

Latest updates to the Reversing Therapy Resistance: Epigenetic-Immune Clinical Trial page
- Check5 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. This is a minor metadata change and does not alter study content.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedA minor site update added Revision: v3.4.2 and removed the previous Revision: v3.4.1 notice along with the government funding lapse banner. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedA site-wide notice about a lapse in government funding was added, and the page revision was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedShow glossary option added; new metadata labels include 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. Older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.SummaryDifference0.2%

- Check62 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4 with no visible changes to study details or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded the California location under Locations. Removed the previous California Locations section and the HHS Vulnerability Disclosure; updated the page revision from v3.3.2 to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Reversing Therapy Resistance: Epigenetic-Immune Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reversing Therapy Resistance: Epigenetic-Immune Clinical Trial page.